Redeye has updated its estimates following Heliospectra’s Q1 2025 report. While the Q1 results were softer than anticipated, management remains optimistic and expects growth to return in the second half of 2025, driven by seasonal patterns and strengthened financial position enabling expanded commercial initiatives and new product launches

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/